• Lymphoma is the most common hematopoeitic tumor in the dog occurring with an estimated incidence of 21.7 cases per 100,000 dogs

  • Poorly defined, heritable risk factors account for an increased incidence of lymphoma subtypes in certain breeds of dog 

  • Similar to the human disease, canine lymphoma consists of a heterogeneous group of tumors with different cells of origin and different clinical behaviors

  • Characteristic translocations and molecular abnormalities are shared between human and canine lymphomas

  • The REAL-WHO system is used to classify lymphomas in both humans and dogs

  • Diffuse Large B cell lymphoma accounts for most canine lymphoma cases

  • Standard of care treatment for DLBCL consists of CHOP-based chemotherapy 

  • Although highly responsive to chemotherapy initially, relapse with drug resistant disease is common and median survival times of approximately 10-14 months are achieved for DLBCL

  • There is a need to improve the outcome of canine patients with lymphoma and the search for these treatments will serve to advance understanding of the disease and improve outcomes for both human and canine patients